Abstract,DOI,ID,PublishedDate,Source,Title,Type,title_words,abstract_words,abstract_sentences
N/A (Too many requests)EMA announced that its human medicines committee (CHMP) has started a rolling review of data on the use of the investigational antiviral medicine remdesivir for the treatment of COVID-19. This means that the CHMP is assessing data as they become available on a rolling basis while development is still ongoing. This is one of the Agency's regulatory tools to speed up the evaluation of a promising investigational treatment during a public health emergency.,10.1016/j.jamda.2020.04.017N/A,DOI:10.1016/j.jamda.2020.04.017N/A,2020-04-2330 April,ELSEVIEREMA,THE GERIATRICIAN: THE FRONTLINE SPECIALIST IN THE TREATMENT OF COVID-19 PATIENTSTreatments and vaccines for COVID-19,Journal of the American Medical Directors AssociationUpdate,"['geriatrician', 'frontline', 'specialist', 'treatment', 'covid', '19', 'patientstreatments', 'vaccine', 'covid', '19']","['n', 'many', 'request', 'ema', 'announce', 'human', 'medicine', 'committee', 'chmp', 'start', 'roll', 'review', 'data', 'use', 'investigational', 'antiviral', 'medicine', 'remdesivir', 'treatment', 'covid', '19', 'mean', 'chmp', 'assess', 'data', 'become', 'available', 'roll', 'basis', 'development', 'still', 'ongoing', 'one', 'agency', 'regulatory', 'tool', 'speed', 'evaluation', 'promise', 'investigational', 'treatment', 'public', 'health', 'emergency']",
"N/A (Too many requests)EMA provided an update on the measures EU authorities are putting in place to support the continued availability of medicines during the pandemic, following a meeting of the EU Executive Steering Group on Shortages of Medicines Caused by Major Events.",10.1016/j.neurol.2020.04.004N/A,DOI:10.1016/j.neurol.2020.04.004N/A,2020-04-2030 April,ELSEVIEREMA,Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases NetworkAvailability of medicines during COVID-19 pandemic,Revue NeurologiqueUpdate,"['guidance', 'care', 'neuromuscular', 'patient', 'covid', '19', 'pandemic', 'outbreak', 'french', 'rare', 'health', 'care', 'neuromuscular', 'disease', 'networkavailability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'provide', 'update', 'measure', 'eu', 'authority', 'put', 'place', 'support', 'continue', 'availability', 'medicine', 'pandemic', 'follow', 'meet', 'eu', 'executive', 'steer', 'group', 'shortage', 'medicine', 'cause', 'major', 'event']",
"N/A (Too many requests)EMA, the European Commission and the Heads of Medicines Agencies updated the Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic. The updated guidance includes more recommendations on simple and flexible measures sponsors can take to manage clinical trials during the COVID-19 pandemic, given the impact it is having on European health systems and society in general.",10.1016/j.jtcvs.2020.04.059N/A,DOI:10.1016/j.jtcvs.2020.04.059N/A,2020-04-2728 April,ELSEVIEREMA,Adult Cardiac Surgery and the COVID-19 Pandemic: Aggressive Infection Mitigation Strategies are Necessary in the Operating Room and Surgical RecoveryGuidance for medicine developers and companies on COVID-19,The Journal of Thoracic and Cardiovascular SurgeryUpdate,"['adult', 'cardiac', 'surgery', 'covid', '19', 'pandemic', 'aggressive', 'infection', 'mitigation', 'strategy', 'necessary', 'operate', 'room', 'surgical', 'recoveryguidance', 'medicine', 'developer', 'company', 'covid', '19']","['n', 'many', 'request', 'ema', 'european', 'commission', 'head', 'medicine', 'agency', 'update', 'guidance', 'management', 'clinical', 'trial', 'covid', '19', 'coronavirus', 'pandemic', 'update', 'guidance', 'include', 'recommendation', 'simple', 'flexible', 'measure', 'sponsor', 'take', 'manage', 'clinical', 'trial', 'covid', '19', 'pandemic', 'give', 'impact', 'european', 'health', 'system', 'society', 'general']",
"N/A (Too many requests)EMA endorsed a joint statement by the members of the International Coalition of Medicines Regulatory Authorities (ICMRA). The statement commits the international regulators to strengthen global collaboration to facilitate rapid development, approval and roll-out of safe and effective medicines against COVID-19.",10.1016/j.fertnstert.2020.04.025N/A,DOI:10.1016/j.fertnstert.2020.04.025N/A,2020-04-1628 April,ELSEVIEREMA,"Prior and Novel Coronaviruses, COVID-19, and Human Reproduction: What Is Known?International Coalition of Medicines Regulatory Authorities (ICMRA)",Fertility and SterilityUpdate,"['prior', 'novel', 'coronaviruses', 'covid', '19', 'human', 'reproduction', 'know', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'ema', 'endorse', 'joint', 'statement', 'member', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra', 'statement', 'commit', 'international', 'regulator', 'strengthen', 'global', 'collaboration', 'facilitate', 'rapid', 'development', 'approval', 'roll', 'safe', 'effective', 'medicine', 'covid', '19']",
"N/A (Too many requests)EMA provided an update on the measures EU authorities are putting in place to support the continued availability of medicines during the pandemic, following a meeting of the EU Executive Steering Group on Shortages of Medicines Caused by Major Events. This includes the development of guidance for pharmaceutical companies responsible for veterinary medicines on adaptations of the regulatory framework to address COVID-19-related challenges.",10.1016/j.athoracsur.2020.04.007N/A,DOI:10.1016/j.athoracsur.2020.04.007N/A,2020-04-2724 April,ELSEVIEREMA,Adult Cardiac Surgery and the COVID-19 Pandemic: Aggressive Infection Mitigation Strategies are Necessary in the Operating Room and Surgical RecoveryAvailability of medicines during COVID-19 pandemic,The Annals of Thoracic SurgeryUpdate,"['adult', 'cardiac', 'surgery', 'covid', '19', 'pandemic', 'aggressive', 'infection', 'mitigation', 'strategy', 'necessary', 'operate', 'room', 'surgical', 'recoveryavailability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'provide', 'update', 'measure', 'eu', 'authority', 'put', 'place', 'support', 'continue', 'availability', 'medicine', 'pandemic', 'follow', 'meet', 'eu', 'executive', 'steer', 'group', 'shortage', 'medicine', 'cause', 'major', 'event', 'include', 'development', 'guidance', 'pharmaceutical', 'company', 'responsible', 'veterinary', 'medicine', 'adaptation', 'regulatory', 'framework', 'address', 'covid', '19', 'relate', 'challenge']",
"N/A (Too many requests)EMA and the national competent authorities reminded patients with suspected or confirmed COVID-19 to report any suspected side effects that they are experiencing with any medicine, including medicines taken to treat COVID-19 and pre-existing conditions. Healthcare professionals treating COVID-19 patients should also report the suspected side effects that their patients are experiencing. These reports help regulators understand how medicines act in patients with COVID-19, complementing the knowledge generated in clinical trials and other studies.",10.1016/j.thromres.2020.04.024N/A,DOI:10.1016/j.thromres.2020.04.024N/A,2020-04-2324 April,ELSEVIEREMA,"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, ItalyPublic-health advice during COVID-19 pandemic",Thrombosis ResearchUpdate,"['venous', 'arterial', 'thromboembolic', 'complication', 'covid', '19', 'patient', 'admit', 'academic', 'hospital', 'milan', 'italypublic', 'health', 'advice', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'national', 'competent', 'authority', 'remind', 'patient', 'suspect', 'confirm', 'covid', '19', 'report', 'suspect', 'side', 'effect', 'experience', 'medicine', 'include', 'medicine', 'take', 'treat', 'covid', '19', 'pre', 'exist', 'condition', 'healthcare', 'professional', 'treat', 'covid', '19', 'patient', 'also', 'report', 'suspect', 'side', 'effect', 'patient', 'experience', 'report', 'help', 'regulator', 'understand', 'medicine', 'act', 'patient', 'covid', '19', 'complement', 'knowledge', 'generate', 'clinical', 'trial', 'study']",
N/A (Too many requests)EMA announced that essential work to combat the COVID-19 pandemic would continue during the Agency’s closure on 27 April and on 1 May 2020.,10.1016/j.ekir.2020.04.001N/A,DOI:10.1016/j.ekir.2020.04.001N/A,2020-04-0423 April,ELSEVIEREMA,"Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, ItalyEMA’s governance during COVID-19 pandemic",Kidney International ReportsUpdate,"['management', 'patient', 'dialysis', 'kidney', 'transplantation', 'sars', 'cov', '2', 'covid', '19', 'pandemic', 'brescia', 'italyema', 'governance', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'announce', 'essential', 'work', 'combat', 'covid', '19', 'pandemic', 'would', 'continue', 'agency', 'closure', '27', 'april', '1', 'may', '2020']",
"N/A (Too many requests)EMA reminded patients and healthcare professionals that chloroquine and hydroxychloroquine medicines are known to potentially cause certain side effects, including heart rhythm problems. Healthcare professionals should carefully consider the possibility of heart rhythm problems when treating COVID-19 patients with these medicines, particularly in patients with pre-existing heart problems and with higher doses, and exercise extra caution when combining treatment with other medicines such as azithromycin that have similar effects on the heart.",10.1016/j.ando.2020.04.005N/A,DOI:10.1016/j.ando.2020.04.005N/A,2020-04-2123 April,ELSEVIEREMA,Renin-angiotensin-aldosterone system and COVID-19 infectionPublic-health advice during COVID-19 pandemic,Annales d'EndocrinologieUpdate,"['renin', 'angiotensin', 'aldosterone', 'system', 'covid', '19', 'infectionpublic', 'health', 'advice', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'remind', 'patient', 'healthcare', 'professional', 'chloroquine', 'hydroxychloroquine', 'medicine', 'know', 'potentially', 'cause', 'certain', 'side', 'effect', 'include', 'heart', 'rhythm', 'problem', 'healthcare', 'professional', 'carefully', 'consider', 'possibility', 'heart', 'rhythm', 'problem', 'treat', 'covid', '19', 'patient', 'medicine', 'particularly', 'patient', 'pre', 'exist', 'heart', 'problem', 'higher', 'do', 'exercise', 'extra', 'caution', 'combine', 'treatment', 'medicine', 'azithromycin', 'similar', 'effect', 'heart']",
"N/A (Too many requests)EMA participated in the global regulators’ meeting on COVID-19-related policy approaches and regulatory flexibility on Thursday, 16 April, under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). Participants discussed high-level policy issues and regulatory challenges related to the rapid development of potential COVID-19 treatments and vaccines and the continued availability of medicines during the pandemic, in particular those used in intensive care. The meeting was the first of a series of bi-weekly meetings organised by ICMRA to allow medicine regulators worldwide to exchange information and build synergies for expediting COVID-19 medicine and vaccine development and approval and avoiding medicine shortages. EMA will chair every other meeting.",10.1016/j.jaci.2020.04.029N/A,DOI:10.1016/j.jaci.2020.04.029N/A,2020-04-2921 April,ELSEVIEREMA,Type I IFN immunoprofiling in COVID-19 patientsInternational Coalition of Medicines Regulatory Authorities (ICMRA),Journal of Allergy and Clinical ImmunologyUpdate,"['type', 'ifn', 'immunoprofiling', 'covid', '19', 'patientsinternational', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'ema', 'participate', 'global', 'regulator', 'meet', 'covid', '19', 'relate', 'policy', 'approach', 'regulatory', 'flexibility', 'thursday', '16', 'april', 'umbrella', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra', 'participant', 'discuss', 'high', 'level', 'policy', 'issue', 'regulatory', 'challenge', 'relate', 'rapid', 'development', 'potential', 'covid', '19', 'treatment', 'vaccine', 'continue', 'availability', 'medicine', 'pandemic', 'particular', 'use', 'intensive', 'care', 'meet', 'first', 'series', 'bi', 'weekly', 'meet', 'organise', 'icmra', 'allow', 'medicine', 'regulator', 'worldwide', 'exchange', 'information', 'build', 'synergy', 'expedite', 'covid', '19', 'medicine', 'vaccine', 'development', 'approval', 'avoid', 'medicine', 'shortage', 'ema', 'chair', 'every', 'meet']",
"N/A (Too many requests)EMA announced that it had launched, together with EU Member States and the pharmaceutical industry, an enhanced fast-track monitoring system to help prevent and mitigate supply issues with crucial medicines used for treating COVID-19 patients. Initially, the system will focus on medicines used in intensive care, which are in greatest demand, before extending to a broader range of medicines. The monitoring system, which involves each pharmaceutical company appointing an industry single point of contact (iSPOC), was set up by the EU Executive Steering Group on Shortages of Medicines Caused by Major Events in cooperation with pharmaceutical companies in the EU.",10.1016/j.therap.2020.04.004N/A,DOI:10.1016/j.therap.2020.04.004N/A,2020-04-2321 April,ELSEVIEREMA,THERAP–COVID-19Availability of medicines during COVID-19 pandemic,TherapiesUpdate,"['therap', 'covid', '19availability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'announce', 'launch', 'together', 'eu', 'member', 'state', 'pharmaceutical', 'industry', 'enhance', 'fast', 'track', 'monitor', 'system', 'help', 'prevent', 'mitigate', 'supply', 'issue', 'crucial', 'medicine', 'use', 'treat', 'covid', '19', 'patient', 'initially', 'system', 'focus', 'medicine', 'use', 'intensive', 'care', 'greatest', 'demand', 'extend', 'broader', 'range', 'medicine', 'monitor', 'system', 'involve', 'pharmaceutical', 'company', 'appoint', 'industry', 'single', 'point', 'contact', 'ispoc', 'set', 'eu', 'executive', 'steer', 'group', 'shortage', 'medicine', 'cause', 'major', 'event', 'cooperation', 'pharmaceutical', 'company', 'eu']",
N/A (Too many requests)EMA decided to continue holding its committee and working-party meetings virtually until the end of May 2020. Stakeholder events planned for May will either be postponed or held virtually. Most EMA staff are also continuing to work remotely until the end of May.,10.1016/j.ijid.2020.04.061N/A,DOI:10.1016/j.ijid.2020.04.061N/A,2020-04-2521 April,ELSEVIEREMA,Mild versus severe COVID-19: laboratory markersEMA’s governance during COVID-19 pandemic,International Journal of Infectious DiseasesUpdate,"['mild', 'versus', 'severe', 'covid', '19', 'laboratory', 'markersema', 'governance', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'decide', 'continue', 'hold', 'committee', 'work', 'party', 'meet', 'virtually', 'end', 'may', '2020', 'stakeholder', 'event', 'plan', 'may', 'either', 'postpone', 'hold', 'virtually', 'ema', 'staff', 'also', 'continue', 'work', 'remotely', 'end', 'may']",
"N/A (Too many requests)The European Commission, EMA and the Heads of Medicine Agencies updated their guidance for pharmaceutical companies on adaptations to the regulatory framework to address COVID-19 challenges to cover good manufacturing practice (GMP) and good distribution practice (GDP) inspections, and the submission of individual case safety reports (ICSRs) to EudraVigilance. EMA published 


additional guidance for qualified persons for pharmcovigilance (QPPV) and marketing authorisation holders

 on how to submit COVID-19-related ICSRs to EudraVigilance, including on the use of the correct Medical Dictionary for Regulatory Activities (MedDRA) terms and free-text fields.",10.1016/j.scitotenv.2020.139115N/A,DOI:10.1016/j.scitotenv.2020.139115N/A,2020-05-0120 April,ELSEVIEREMA,Asymmetric nexus between temperature and COVID-19 in the top ten affected provinces of China: A current application of quantile-on-quantile approachGuidance for medicine developers and companies on COVID-19,Science of The Total EnvironmentUpdate,"['asymmetric', 'nexus', 'temperature', 'covid', '19', 'top', 'ten', 'affect', 'province', 'china', 'current', 'application', 'quantile', 'quantile', 'approachguidance', 'medicine', 'developer', 'company', 'covid', '19']","['n', 'many', 'request', 'european', 'commission', 'ema', 'head', 'medicine', 'agency', 'update', 'guidance', 'pharmaceutical', 'company', 'adaptation', 'regulatory', 'framework', 'address', 'covid', '19', 'challenge', 'cover', 'good', 'manufacture', 'practice', 'gmp', 'good', 'distribution', 'practice', 'gdp', 'inspection', 'submission', 'individual', 'case', 'safety', 'report', 'icsrs', 'eudravigilance', 'ema', 'publish', 'additional', 'guidance', 'qualify', 'person', 'pharmcovigilance', 'qppv', 'market', 'authorisation', 'holder', 'submit', 'covid', '19', 'relate', 'icsrs', 'eudravigilance', 'include', 'use', 'correct', 'medical', 'dictionary', 'regulatory', 'activity', 'meddra', 'term', 'free', 'text', 'field']",
"N/A (Too many requests)EMA provided an update on the measures EU authorities are putting place to support the continued availability of medicines during the pandemic, following a meeting of the EU Executive Steering Group on Shortages of Medicines Caused by Major Events. The update covers progress made in setting up an enhanced monitoring system for supply issues with crucial medicines for the treatment of COVID-19 and planned updates to the guidance for pharmaceutical companies on adaptations of the regulatory framework to address COVID-19-related challenges.",10.1016/j.numecd.2020.04.013N/A,DOI:10.1016/j.numecd.2020.04.013N/A,2020-04-1820 April,ELSEVIEREMA,Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19Availability of medicines during COVID-19 pandemic,"Nutrition, Metabolism and Cardiovascular DiseasesUpdate","['cardiovascular', 'disease', 'potentially', 'contribute', 'progression', 'poor', 'prognosis', 'covid', '19availability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'provide', 'update', 'measure', 'eu', 'authority', 'put', 'place', 'support', 'continue', 'availability', 'medicine', 'pandemic', 'follow', 'meet', 'eu', 'executive', 'steer', 'group', 'shortage', 'medicine', 'cause', 'major', 'event', 'update', 'cover', 'progress', 'make', 'set', 'enhance', 'monitor', 'system', 'supply', 'issue', 'crucial', 'medicine', 'treatment', 'covid', '19', 'plan', 'update', 'guidance', 'pharmaceutical', 'company', 'adaptation', 'regulatory', 'framework', 'address', 'covid', '19', 'relate', 'challenge']",
"N/A (Too many requests)The International Coalition of Medicines Regulatory Authorities published a report summarising the third global regulatory workshop on the use of observational studies and real-world data in generating robust evidence on the safety and efficacy of COVID-19 vaccines and treatments. The report provides a snapshot of ongoing and planned observational studies, platforms and registries in various countries and regions around the world. EMA co-chaired the meeting with Health Canada.",10.1016/j.bbi.2020.04.077N/A,DOI:10.1016/j.bbi.2020.04.077N/A,2020-04-2816 April,ELSEVIEREMA,COVID-19 presenting as strokeInternational Coalition of Medicines Regulatory Authorities (ICMRA),"Brain, Behavior, and ImmunityUpdate","['covid', '19', 'present', 'strokeinternational', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'publish', 'report', 'summarise', 'third', 'global', 'regulatory', 'workshop', 'use', 'observational', 'study', 'real', 'world', 'data', 'generate', 'robust', 'evidence', 'safety', 'efficacy', 'covid', '19', 'vaccine', 'treatment', 'report', 'provide', 'snapshot', 'ongoing', 'plan', 'observational', 'study', 'platform', 'registry', 'various', 'country', 'region', 'around', 'world', 'ema', 'co', 'chair', 'meet', 'health', 'canada']",
"N/A (Too many requests)EMA, the European Commission and the European medicines regulatory network published guidance for companies on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients.",10.1016/j.oraloncology.2020.104741N/A,DOI:10.1016/j.oraloncology.2020.104741N/A,2020-04-2810 April,ELSEVIEREMA,What Dentists Need to Know about COVID-19Availability of medicines during COVID-19 pandemic,Oral OncologyUpdate,"['dentist', 'need', 'know', 'covid', '19availability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'european', 'commission', 'european', 'medicine', 'regulatory', 'network', 'publish', 'guidance', 'company', 'adaptation', 'regulatory', 'framework', 'address', 'challenge', 'arise', 'covid', '19', 'pandemic', 'particular', 'focus', 'crucial', 'medicine', 'use', 'covid', '19', 'patient']",
N/A (Too many requests)EMA provided an update on the measures EU authorities are putting place to support the continued availability of medicines during the pandemic. This covers the enhanced monitoring system for supply issues with crucial medicines for the treatment of COVID-19 and the guidance currently under development on the regulatory rules that could be applied with greater flexibility to help secure their continued supply.,10.1016/j.bbih.2020.100064N/A,DOI:10.1016/j.bbih.2020.100064N/A,2020-03-2910 April,ELSEVIEREMA,Knowledge and attitudes of medical staff in Chinese psychiatric hospitals regarding COVID-19Availability of medicines during COVID-19 pandemic,"Brain, Behavior, & Immunity - HealthUpdate","['knowledge', 'attitude', 'medical', 'staff', 'chinese', 'psychiatric', 'hospital', 'regard', 'covid', '19availability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'provide', 'update', 'measure', 'eu', 'authority', 'put', 'place', 'support', 'continue', 'availability', 'medicine', 'pandemic', 'cover', 'enhance', 'monitor', 'system', 'supply', 'issue', 'crucial', 'medicine', 'treatment', 'covid', '19', 'guidance', 'currently', 'development', 'regulatory', 'rule', 'could', 'apply', 'greater', 'flexibility', 'help', 'secure', 'continue', 'supply']",
"N/A (Too many requests)EMA published the 


mandate of its COVID-19 EMA pandemic Task Force (COVID-ETF).

 The Task Force is helping EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19.",10.1016/j.mehy.2020.109762N/A,DOI:10.1016/j.mehy.2020.109762N/A,2020-04-229 April,ELSEVIEREMA,The Powerful Immune System Against Powerful COVID-19: A HypothesisEMA’s governance during COVID-19 pandemic,Medical HypothesesUpdate,"['powerful', 'immune', 'system', 'powerful', 'covid', '19', 'hypothesisema', 'governance', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'publish', 'mandate', 'covid', '19', 'ema', 'pandemic', 'task', 'force', 'covid', 'etf', 'task', 'force', 'help', 'eu', 'member', 'state', 'european', 'commission', 'take', 'quick', 'coordinate', 'regulatory', 'action', 'development', 'authorisation', 'safety', 'monitor', 'treatment', 'vaccine', 'intend', 'treatment', 'prevention', 'covid', '19']",
N/A (Too many requests)The International Coalition of Medicines Regulatory Authorities published the report summarising the second global regulatory workshop on COVID-19 medicine development held on Thursday 2 April. The report stresses the need for robust evidence to show which potential treatments work. EMA co-chaired the meeting.,10.1016/j.clinimag.2020.04.023N/A,DOI:10.1016/j.clinimag.2020.04.023N/A,2020-04-249 April,ELSEVIEREMA,COVID-19 pneumonia patient without clear epidemiological history outside Wuhan: An analysis of the radiographic and clinical featuresInternational Coalition of Medicines Regulatory Authorities (ICMRA),Clinical ImagingUpdate,"['covid', '19', 'pneumonia', 'patient', 'without', 'clear', 'epidemiological', 'history', 'outside', 'wuhan', 'analysis', 'radiographic', 'clinical', 'featuresinternational', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'publish', 'report', 'summarise', 'second', 'global', 'regulatory', 'workshop', 'covid', '19', 'medicine', 'development', 'hold', 'thursday', '2', 'april', 'report', 'stress', 'need', 'robust', 'evidence', 'show', 'potential', 'treatment', 'work', 'ema', 'co', 'chair', 'meet']",
N/A (Too many requests)EMA and Health Canada jointly chaired the third global regulatory workshop on Monday 6 April under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). The participants discussed how data generated during clinical practice in the treatment of COVID-19 could complement evidence from clinical trials of potential COVID-19 treatments and vaccines.,10.1016/j.jcv.2020.104379N/A,DOI:10.1016/j.jcv.2020.104379N/A,2020-04-227 April,ELSEVIEREMA,COVID-19 in Vietnam: A lesson of pre-preparationInternational Coalition of Medicines Regulatory Authorities (ICMRA),Journal of Clinical VirologyUpdate,"['covid', '19', 'vietnam', 'lesson', 'pre', 'preparationinternational', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'ema', 'health', 'canada', 'jointly', 'chair', 'third', 'global', 'regulatory', 'workshop', 'monday', '6', 'april', 'umbrella', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra', 'participant', 'discuss', 'data', 'generate', 'clinical', 'practice', 'treatment', 'covid', '19', 'could', 'complement', 'evidence', 'clinical', 'trial', 'potential', 'covid', '19', 'treatment', 'vaccine']",
N/A (Too many requests)EMA announced that essential work to combat the COVID-19 pandemic would continue during the Agency’s Easter break from 9 to 13 April 2020.,10.1016/j.dsx.2020.03.011N/A,DOI:10.1016/j.dsx.2020.03.011N/A,2020-03-267 April,ELSEVIEREMA,Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countriesEMA’s governance during COVID-19 pandemic,Diabetes & Metabolic Syndrome: Clinical Research & ReviewsUpdate,"['chloroquine', 'hydroxychloroquine', 'treatment', 'covid', '19', 'without', 'diabetes', 'systematic', 'search', 'narrative', 'review', 'special', 'reference', 'india', 'develop', 'countriesema', 'governance', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'announce', 'essential', 'work', 'combat', 'covid', '19', 'pandemic', 'would', 'continue', 'agency', 'easter', 'break', '9', '13', 'april', '2020']",
"N/A (Too many requests)EMA announced new EU-level measures to help prevent and mitigate supply issues with medicines used to treat COVID-19 patients. These include enhanced coordination with the pharmaceutical industry in monitoring supply issues and regulatory actions to support companies in increasing the available supply of critical medicines. During this extraordinary health crisis, EMA will act as the central EU coordinator, supporting Member States' activities in preventing and mitigating supply issues.",10.1016/j.jviscsurg.2020.04.011N/A,DOI:10.1016/j.jviscsurg.2020.04.011N/A,2020-04-186 April,ELSEVIEREMA,Management of the COVID-19 epidemic by public health establishments - Analysis by the Fédération Hospitalière de FranceAvailability of medicines during COVID-19 pandemic,Journal of Visceral SurgeryUpdate,"['management', 'covid', '19', 'epidemic', 'public', 'health', 'establishment', 'analysis', 'f', 'ration', 'hospitali', 'de', 'franceavailability', 'medicine', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'announce', 'new', 'eu', 'level', 'measure', 'help', 'prevent', 'mitigate', 'supply', 'issue', 'medicine', 'use', 'treat', 'covid', '19', 'patient', 'include', 'enhance', 'coordination', 'pharmaceutical', 'industry', 'monitor', 'supply', 'issue', 'regulatory', 'action', 'support', 'company', 'increase', 'available', 'supply', 'critical', 'medicine', 'extraordinary', 'health', 'crisis', 'ema', 'act', 'central', 'eu', 'coordinator', 'support', 'member', 'state', 'activity', 'prevent', 'mitigate', 'supply', 'issue']",
N/A (Too many requests)EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used in compassionate use programmes across Europe when treating COVID-19 patients who are not eligible for inclusion in clinical trials. These recommendations aim to ensure a harmonised approach across EU Member States. They also explain which group of patients may benefit from treatment and provide preliminary information on the medicine’s safety.,10.1016/j.jtcvs.2020.03.061N/A,DOI:10.1016/j.jtcvs.2020.03.061N/A,2020-04-093 April,ELSEVIEREMA,COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement from Thoracic Surgery Outcomes Research NetworkTreatments and vaccines for COVID-19,The Journal of Thoracic and Cardiovascular SurgeryUpdate,"['covid', '19', 'guidance', 'triage', 'operation', 'thoracic', 'malignancy', 'consensus', 'statement', 'thoracic', 'surgery', 'outcome', 'research', 'networktreatments', 'vaccine', 'covid', '19']","['n', 'many', 'request', 'ema', 'human', 'medicine', 'committee', 'chmp', 'give', 'recommendation', 'investigational', 'antiviral', 'medicine', 'remdesivir', 'use', 'compassionate', 'use', 'programme', 'across', 'europe', 'treat', 'covid', '19', 'patient', 'eligible', 'inclusion', 'clinical', 'trial', 'recommendation', 'aim', 'ensure', 'harmonise', 'approach', 'across', 'eu', 'member', 'state', 'also', 'explain', 'group', 'patient', 'may', 'benefit', 'treatment', 'provide', 'preliminary', 'information', 'medicine', 'safety']",
N/A (Too many requests)EMA and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) jointly chaired the second global regulatory workshop on Thursday 2 April under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). The participants discussed the progress made in the development of potential COVID-19 treatments and reaffirmed the need for large clinical trials to generate conclusive evidence on which treatments work. ICMRA will publish a summary report of the meeting shortly.,10.1016/j.ajogmf.2020.100110N/A,DOI:10.1016/j.ajogmf.2020.100110N/A,2020-03-253 April,ELSEVIEREMA,Labor and delivery guidance for COVID-19International Coalition of Medicines Regulatory Authorities (ICMRA),American Journal of Obstetrics & Gynecology MFMUpdate,"['labor', 'delivery', 'guidance', 'covid', '19international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra']","['n', 'many', 'request', 'ema', 'japanese', 'pharmaceutical', 'medical', 'device', 'agency', 'pmda', 'jointly', 'chair', 'second', 'global', 'regulatory', 'workshop', 'thursday', '2', 'april', 'umbrella', 'international', 'coalition', 'medicine', 'regulatory', 'authority', 'icmra', 'participant', 'discuss', 'progress', 'make', 'development', 'potential', 'covid', '19', 'treatment', 'reaffirm', 'need', 'large', 'clinical', 'trial', 'generate', 'conclusive', 'evidence', 'treatment', 'work', 'icmra', 'publish', 'summary', 'report', 'meet', 'shortly']",
N/A (Too many requests)EMA advised patients and healthcare professionals to only use chloroquine and hydroxychloroquine medicines for their authorised indications or as part of clinical trials or national emergency use programmes for the treatment of COVID-19. This is to ensure patient safety and the best use of available supplies.,10.1016/j.jns.2020.116832N/A,DOI:10.1016/j.jns.2020.116832N/A,2020-04-111 April,ELSEVIEREMA,Central nervous system manifestations of COVID-19: A systematic reviewPublic-health advice during COVID-19 pandemic,Journal of the Neurological SciencesUpdate,"['central', 'nervous', 'system', 'manifestation', 'covid', '19', 'systematic', 'reviewpublic', 'health', 'advice', 'covid', '19', 'pandemic']","['n', 'many', 'request', 'ema', 'advise', 'patient', 'healthcare', 'professional', 'use', 'chloroquine', 'hydroxychloroquine', 'medicine', 'authorise', 'indication', 'part', 'clinical', 'trial', 'national', 'emergency', 'use', 'programme', 'treatment', 'covid', '19', 'ensure', 'patient', 'safety', 'best', 'use', 'available', 'supply']",
N/A (Too many requests)EMA announced that it has held discussions with developers of around 40 potential treatments and a dozen vaccines against COVID-19. No potential COVID-19 treatments had demonstrated efficacy based on the preliminary data available. EMA welcomes the launch of large clinical trials to test promising treatments and to generate conclusive evidence. Two vaccines had already entered phase I clinical trials. EMA estimated that it might take at least a year before a vaccine is ready for approval and available in sufficient quantities to enable widespread use.,10.1016/j.chest.2020.03.032N/A,DOI:10.1016/j.chest.2020.03.032N/A,2020-03-2631 Match,ELSEVIEREMA,Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1Treatments and vaccines for COVID-19,ChestUpdate,"['comparison', 'hospitalize', 'patient', 'ards', 'cause', 'covid', '19', 'h1n1treatments', 'vaccine', 'covid', '19']","['n', 'many', 'request', 'ema', 'announce', 'hold', 'discussion', 'developer', 'around', '40', 'potential', 'treatment', 'dozen', 'vaccine', 'covid', '19', 'potential', 'covid', '19', 'treatment', 'demonstrate', 'efficacy', 'base', 'preliminary', 'data', 'available', 'ema', 'welcome', 'launch', 'large', 'clinical', 'trial', 'test', 'promise', 'treatment', 'generate', 'conclusive', 'evidence', 'two', 'vaccine', 'already', 'enter', 'phase', 'clinical', 'trial', 'ema', 'estimate', 'might', 'take', 'least', 'year', 'vaccine', 'ready', 'approval', 'available', 'sufficient', 'quantity', 'enable', 'widespread', 'use']",
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
,,,,,,,N/A,N/A,N/A
